Projects per year
Personal profile
Headline
Biography
Fingerprint
- 1 Similar Profiles
Network
-
-
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
Bhardwaj, N., Bhardwaj, N., Galsky, M., Zhu, J. J., Galsky, M. & Zhu, J.
1/04/20 → 31/03/23
Project: Research
-
Cancer Research Institute Grants
Subudhi, S. S., Graff, J. J., Weintzel, K. K., Autio, K. K., Fong, L. L. & Galsky, M.
1/01/18 → …
Project: Research
-
Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring
Martini, A., Yu, M., Raggi, D., Joshi, H., Fallara, G., Montorsi, F., Necchi, A. & Galsky, M. D., 1 Aug 2022, In: Cancer. 128, 15, p. 2892-2897 6 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis
Fallara, G., Belladelli, F., Robesti, D., Raggi, D., Nocera, L., Marandino, L., Galsky, M. D., Montorsi, F., Malavaud, B., Ploussard, G., Necchi, A. & Martini, A., Nov 2022, In: Critical Reviews in Oncology/Hematology. 179, 103801.Research output: Contribution to journal › Review article › peer-review
-
Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (Nature Medicine, (2022), 28, 4, (626-629), 10.1038/s41591-022-01681-x)
Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman-Yassky, E., Ungar, B., Mehandru, S., Golas, B. J., Labow, D., Sfakianos, J., Nair, S. S., Chakravarty, D., Buckstein, M., Song, X., Kenigsberg, E., Gnjatic, S., & 6 others , Aug 2022, In: Nature Medicine. 28, 8, p. 1723 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Biomarkers for therapy selection in metastatic urothelial cancer
Jun, T., Anker, J. & Galsky, M. D., 2022, In: Journal of Cancer Metastasis and Treatment. 8, 1.Research output: Contribution to journal › Review article › peer-review
Open Access1 Scopus citations -
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
Nikolos, F., Hayashi, K., Hoi, X. P., Alonzo, M. E., Mo, Q., Kasabyan, A., Furuya, H., Trepel, J., Di Vizio, D., Guarnerio, J., Theodorescu, D., Rosser, C., Apolo, A., Galsky, M. & Chan, K. S., Dec 2022, In: Nature Communications. 13, 1, 1487.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations
Press/Media
-
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
8/03/23
1 item of Media coverage
Press/Media
-
Dr. Galsky on the Rationale for the CheckMate-274 Trial in Urothelial Cancer
8/03/23
1 item of Media coverage
Press/Media
-
Extended Follow-Up Reaffirms Benefit of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma
7/03/23
1 item of Media coverage
Press/Media
-
Risk-Adapted Approach for Muscle-Invasive Bladder Cancer Requires Further Refinement
1/03/23
1 item of Media coverage
Press/Media
-
Adjuvant nivolumab as standard of care in resected bladder cancer
22/02/23
2 items of Media coverage
Press/Media